For Healthcare Professionals

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors


About the study

To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and ovarian cancer (OC). A combination of nivolumab with ipilimumab and cobimetinib is also investigated in PC.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


  • For more information regarding BMS clinical trial participation, please visit
  • Inclusion Criteria:

    1. Subjects with histologically or cytologically confirmed locally advanced or metastatic disease of the following tumor types:
    2. Triple Negative Breast Cancer
    3. Gastric Cancer
    4. Pancreatic Cancer
    5. Small Cell Lung Cancer
    6. Bladder Cancer
    7. Ovarian Cancer
    8. Subjects must have measurable disease
    9. Eastern Cooperative Oncology Group (ECOG) of 0 or 1
    10. Adequate hematological and organ function as confirmed by laboratory values


    Exclusion Criteria:

    1. Active brain metastases or leptomeningeal metastases
    2. Subjects with active, known or suspected autoimmune disease
    3. Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatment
    4. Prior therapy with experimental anti-tumor vaccines; any T cell co-stimulation or checkpoint pathways, such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, including Ipilimumab; or other medicines specifically targeting T cell is also prohibited

    pin location

    Study Locations

    Enter your ZIP code/Postal code/PIN code to locate study sites near you:

    How to Apply

    Contact the study center to learn if this study is a good match for you.

    Study’s details


    Advanced or Metastatic Solid Tumors

    Age (in years)



    Phase 1/Phase 2

    Participants needed


    Est. Completion Date

    Dec 31, 2023

    Treatment type



    Bristol-Myers Squibb identifier


    Study number


    Understanding Clinical Trials

    Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


    Sign up to save your favorites, 
    receive newsletters, resources, and alerts 
    about clinical trials related to your conditions of interest.